Sean Mackay - 20 Mar 2026 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Reporting relationship: SVP & Chief Business Officer
Issuer ticker: LAB
Reported as of: 20 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Apr 2026, 21:55:04 UTC
Prior SEC filing: 24 Feb 2026
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Sean Mackay by Samantha M. Silver, Attorney-in-Fact

Key filing fact

Sean Mackay filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 08 Apr 2026.

Key facts

This page summarizes Sean Mackay's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Apr 2026, 21:55.

Change

Previous filing in this sequence was filed on 24 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001875501 Primary reporting owner

Mackay Sean

Relationship: SVP & Chief Business Officer
Address: C/O STANDARD BIOTOOLS INC., 50 MILK STREET, 10TH FLOOR, BOSTON
Signature: /s/ Sean Mackay by Samantha M. Silver, Attorney-in-Fact
Signature date: 08 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LAB transaction

Common Stock

Award

Transaction value
Shares: +272,107
Change %: +36%
Price: $0.000000^*
Shares after: 1,032,281
Date: 20 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LAB transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares: +612,240
Change %
Price: $0.000000^*
Shares after: 612,240
Date: 20 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 612,240
Exercise price: $0.9846
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

Footnote F2

The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.